国际肿瘤学杂志

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (6): 426-429.doi: 10.3760/cma.j.issn.1673-422X.2015.06.007

• 论著 • 上一篇    下一篇

奥沙利铂联合替吉奥或多西他赛治疗进展期胃癌的临床疗效分析

杨世荣,赵成茂,王嵘,穆元忠,赵刚   

  1. 810007西宁，青海省第五人民医院肿瘤三科
  • 收稿日期:2014-12-25 出版日期:2015-06-08 发布日期:2015-05-31
  • 通讯作者: 杨世荣，Email：250485476@qq.com E-mail:250485476@qq.com

Clinical evaluation of oxaliplatin combined with S-1 or docetaxel for advanced gastric cancer

Yang Shirong, Zhao Chengmao, Wang Rong, Mu Yuanzhong, Zhao Gang   

  1. Department of Oncology, Fifth People′s Hospital of Qinghai Province, Xining 810007, China
  • Received:2014-12-25 Online:2015-06-08 Published:2015-05-31
  • Contact: Yang Shirong E-mail:250485476@qq.com

PDF

1190

被引次数

2

摘要： 目的 比较奥沙利铂联合多西他赛或替吉奥治疗进展期胃癌(AGC)的疗效及安全性。方法 选取2011年4月—2013年1月在青海省第五人民医院住院的AGC患者共62例，采用随机数字表法将患者随机分为两组，A组31例接受奥沙利铂联合替吉奥方案，B组31例接受奥沙利铂联合多西他赛方案；比较两组反应率（RR）、疾病控制率（DCR）、疾病无进展时间、总生存时间和不良反应。结果 A组RR、DCR、中位疾病无进展时间（mPFS）、中位生存时间（mOS）分别为48.4%、67.7%、5.4个月、9.0个月；B组相应为54.8%、77.4%、6.2个月、9.8个月，差异均无统计学意义（χ2=0.26，P=0.711；χ2=0.73，P=0.393； χ2=0.51，P=0.473； χ2=0.03，P=0.829）。A组Ⅰ～Ⅱ级外周神经毒性(9.7%∶22.6%)及恶心呕吐发生率（12.9%∶32.3%）均低于B组（χ2=5.78，P=0.002；χ2=4.63，P=0.016）。结论 两种化疗方案治疗AGC的疗效相当，奥沙利铂联合替吉奥方案可作为进展期胃癌的一种化疗方案，且在耐受性方面优于奥沙利铂联合多西他赛方案。

关键词: 胃肿瘤, 药物疗法, 奥沙利铂, 多西他赛, 替吉奥

Abstract: Objective To evaluate the efficacy and safety of combination therapy of oxaliplatin and S1 vs oxaliplatin and docetaxel for advanced gastric cancer (AGC) patients. Methods From April 2011 to January 2013, 62 cases of AGC were collected in the Fifth People′s Hospital of Qinghai Province. All cases were randomly divided into group A (31 cases) and B (31 cases) by random number table. In group A, oxaliplatin plus S-1 was administered, and in group B, oxaliplatin plus docetaxel was applied. The response rate (RR), time of diseases controlled rate (DCR), progressionfree survival (PFS), overall survival (OS) and adverse reactions of the two groups were observed and compared. Results There were no statistically differences between group A and group B in RR (48.4% vs 54.8%), DCR (67.7% vs 77.4%), mPFS (5.4 months vs 6.2 months), mOS (9.0 months vs 9.8 months), and the statistical values were as follows: χ2=0.26, P=0.711; χ2 =0.73, P=0.393; χ2=0.51, P=0.473; χ2=0.03, P=0.829. The incidence of degrees Ⅰ-Ⅱ peripheral neuropathy (9.7% vs 22.6%), nausea and vomiting (12.9% vs 32.3%) in group A were significantly lower than those in group B (χ2=5.78, P=0.002; χ2=4.63, P=0.016). Conclusion Both the two chemotherapies are similar in therapeutic effect for patients with AGC. Oxaliplatin plus S-1 treatment may be better than oxaliplatin plus docetaxel in the tolerance of patients.

Key words: Stomach neoplasms, Drug therapy, Oxaliplatin, Docetaxel, S-1